Aristotelis Bamias is a Professor at the Medical School of the University of Athens, Greece. He studied Μedicine at the University of Athens and trained in Ιnternal Μedicine and Μedical Οncology at the Hammersmith, Royal Marsden, and St Bartholomew’s Ηospitals in London, UK. Professor Bamias completed his thesis at the University of Athens and obtained a PhD from the University of London, working on the application of monoclonal antibodies to cancer diagnosis and treatment. He has also served as a lecturer in Medical Oncology at the University of London. He is now a practicing medical oncologist at the 2nd Propaedeutic Department of Internal Medicine of the University of Athens, Attikon University Hospital, Athens, Greece, and was director of this department from 2019 to September 2022.

Professor Bamias’s main research focus is urogenital and gynecological tumors. He was the coordinator of the genito-urinary working group of the Hellenic Cooperative Oncology Group (HECOG) for 10 years and the representative of HECOG at the European Network Gynaecological Oncological Trial Groups (ENGOT) for 3 years. Professor Bamias is a founding member and Chair of the Hellenic Genito-Urinary Cancer Group (HGUCG). He is also a member of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and a Retrospective International Study of Cancers of the Urothelial Tract (RISC) investigator.

Professor Bamias is a member of the Royal College of Physicians (MRCP, UK), and a full member of ESMO, ASCO, and the European Society of Gynaecological Oncology (ESGO). He has been a member of the ESMO Faculty for Genitourinary Cancer since 2012 and he chaired this group from 2016 to 2020. He has been member of the scientific committees of ESMO and EMUC Congresses since 2016, invited faculty in the respective congresses, and has organized several ESMO educational activities. A member of several international advisory boards, steering committees of international trials and consensus groups, he has led numerous national and international, industry-sponsored and academic studies, and he has published more than 300 original papers and reviews in peer-reviewed journals, including N Engl J Med, Lancet, Lancet Oncology, and J Clin Oncol.

Thomas Powles is Professor of Genitourinary Oncology and Director of Barts Cancer Centre in London, UK. He trained in medical oncology at Imperial College London, UK, and completed his post-graduate training in oncology in 2005, receiving an MD from the University of London in 2006, with a thesis on the mechanisms of resistance to therapy in urological cancers. Prof. Powles is the lead for solid tumor research at Barts Cancer Institute, London, leading a spectrum of clinical trials across phase I–III, including biomarker, novel targeted, and immune therapies studies. He is the author of over 300 peer-reviewed publications in all the major medical journals. Prof. Powles participates in, or leads, a number of guidelines committees.

Robert (Rob) Coleman is Emeritus Professor of Medical Oncology in the Department of Oncology and Metabolism at the University of Sheffield, UK. He graduated in medicine from King’s College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991; he was instrumental in developing clinical cancer research in Sheffield and established an internationally respected bone oncology research team in the city. Professor Coleman has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network. He has published over 450 peer-reviewed manuscripts and numerous book chapters, and is a Past-President of the Cancer and Bone Society and the founding editor of Journal of Bone Oncology.

During 2014–2019, Professor Coleman was a part-time Medical Director for the global independent medical education provider, prIME Oncology, developing and delivering both live and online educational activities for oncologists and other providers of cancer care. Since retiring from his formal position at the university in 2017, he remains active in research, lectures on his areas of expertise around the world, and provides consultancy to a medical education company as well as a range of pharma and biotech companies developing new oncology treatments.